Enhances mission to advance the care of
patients facing the potential diagnosis of a neurodegenerative
disease
SCOTTSDALE, Ariz., June 26,
2024 /PRNewswire/ -- CND Life Sciences (CND), a
medical technology company pioneering the development of cutaneous
neurodiagnostic tests and associated biomarker services, today
announced the expansion of its leadership team by welcoming four
new executives. Hernan Lopez joins
CND as Chief Operating Officer, Kathryn Van
Wie as Vice President of Strategy & Business
Development, Annemarie Benton as
Vice President of Market Access, and Bryan
May as Vice President of Information Technology.
"We are thrilled to welcome this outstanding group of
world-class leaders to the CND executive team," said Richard J. Morello, Chief Executive Officer of
CND Life Sciences. "With their deep breadth of experience in
healthcare, medical devices, life science, and biotech, we are
well-positioned to expand our work helping physicians and patients
detect and treat neurodegenerative diseases easier, safer, and more
effectively than ever before."
As Chief Operating Officer, Hernan
Lopez will provide strategic leadership and drive
operational excellence across a range of functional areas within
CND. He has an unprecedented track record and nearly 20 years of
experience in medical device and life sciences companies. Prior to
joining CND, Hernan was the Executive Vice President of Operations
at GT Medical Technology, where he successfully brought an
innovative medical device for the treatment of brain cancer to
market. Prior to GT Medical Technologies, Hernan successfully
managed explosive growth venture-backed company operations with
successful exits, supported post-merger integrations, and worked in
several operations roles in contract manufacturing organizations as
well as multinational medical device companies such as Boston
Scientific.
Regarding his new appointment, Hernan
Lopez remarked, "I am excited to join CND as a true
pioneer in the field of neurodegenerative diseases. I look forward
to collaborating with CND's talented and dedicated team to advance
our patient mission during this next phase of growth."
Kathryn Van Wie, Vice President
of Strategy & Business Development, will focus on key strategic
initiatives including CND's biomarker capabilities for
pharmaceutical clinical trials, international market expansion, and
growing partnerships leveraging complementary technologies. Kathryn
is an attorney who spent a decade at Vertex Pharmaceuticals as
Corporate Counsel and subsequently in US Marketing and as Chief of
Staff in Commercial Strategy and Operations.
Annemarie Benton, Vice President
of Market Access, will oversee the development and execution of
CND's market access and payer engagement strategies. Annemarie
brings more than 17 years of experience in the life sciences and
advanced diagnostic laboratory industries. She began her career as
a molecular scientist and leverages her clinical background to
advocate for the adoption of precision medicine solutions by
navigating the evolving payer landscape. Prior to joining CND,
Annemarie was Head of Managed Care at Bionano and led the payer
relations and managed care department at Caris Life Sciences.
Bryan May, Vice President of
Information Technology, will be responsible for all IT functions.
With over 25 years of experience across diverse industries
including healthcare, distribution, supply chain, and contract
manufacturing, Bryan brings a proven track record of driving
digital transformation, optimizing IT infrastructure, and
implementing solutions to enhance operational efficiency and
strategic growth. Prior to joining CND, Bryan worked at Atara
Biotherapeutics where he supported infrastructure and cloud
services across 3 sites. Before that, he served as the Senior
Director of Infrastructure Services and Cloud Engineering at
McKesson for 15 years.
About CND Life Sciences
CND Life Sciences supports the care of patients facing the
potential diagnosis of a neurodegenerative disease and other
neurological conditions. Operating a CLIA-certified and
CAP-accredited laboratory in Scottsdale,
Arizona, CND provides the Syn-One Test® to
clinicians and patients across the US as the world's only
commercially available test to detect, visualize, and quantify
phosphorylated alpha-synuclein located in cutaneous nerves. This
abnormal form of the alpha-synuclein protein is the pathological
hallmark of Parkinson's disease, dementia with Lewy bodies, and
other synucleinopathies. Results of a recent prospective,
multicenter NIH-sponsored study of the Syn-One Test® was
published in the Journal of the American Medical Association
demonstrating >95% positivity in patients with a clinically
determined synucleinopathy.1 The study outcomes further
support Syn-One's role as an accurate diagnostic tool for use both
in clinical practice and in biopharma clinical trials. The test
analyzes small skin biopsy samples collected in a clinician's
office through a 15-minute patient procedure and includes an
assessment of intraepidermal nerve fiber density and other
important pathologic markers. The Company collaborates with
biopharmaceutical companies on clinical trials for investigational
therapies targeting neurodegenerative diseases and is also
conducting studies assessing the test's ability to provide early
disease detection and prognostic insights. For more information,
visit cndlifesciences.com or connect with us on LinkedIn.
Contact:
Lisa DeScenza
LaVoieHealthScience
(978) 395-5970
ldescenza@lavoiehealthscience.com
Disclosure: Research reported in this publication was supported
by the National Institute of Neurological Disorders and Stroke and
the National Institute on Aging (NIA) of the National Institutes of
Health under Award Numbers R44NS117214, R44AG076072, and
R44NS127696. The content is solely the responsibility of the
authors and does not necessarily represent the official views of
the National Institutes of Health.
1Gibbons CH, Levine T, Adler C, et al. Skin Biopsy
Detection of Phosphorylated α-Synuclein in Patients With
Synucleinopathies. JAMA. Published online March 20, 2024. doi:10.1001/jama.2024.0792.
View original content to download
multimedia:https://www.prnewswire.com/news-releases/cnd-life-sciences-expands-leadership-team-with-four-key-executive-appointments-302182385.html
SOURCE CND Life Sciences